🚀 VC round data is live in beta, check it out!
Sanofi India Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sanofi India and similar public comparables like Bright Minds Biosciences, Basilea Pharmaceutica, MannKind, LB Pharmaceuticals and more.
Sanofi India Overview
About Sanofi India
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.
Founded
1956
HQ
Employees
991
Website
Sectors
Financials (LTM)
EV
$855M
Sanofi India Financials
Sanofi India reported last 12-month revenue of $204M and EBITDA of $55M.
In the same LTM period, Sanofi India generated $55M in EBITDA and $39M in net income.
Revenue (LTM)
Sanofi India P&L
In the most recent fiscal year, Sanofi India reported revenue of $202M and EBITDA of $54M.
Sanofi India expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $204M | XXX | $202M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $99M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $55M | XXX | $54M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $39M | XXX | $38M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 19% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sanofi India Stock Performance
Sanofi India has current market cap of $881M, and enterprise value of $855M.
Market Cap Evolution
Sanofi India's stock price is $38.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $855M | $881M | 0.4% | XXX | XXX | XXX | $1.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSanofi India Valuation Multiples
Sanofi India trades at 4.2x EV/Revenue multiple, and 15.5x EV/EBITDA.
EV / Revenue (LTM)
Sanofi India Financial Valuation Multiples
As of April 18, 2026, Sanofi India has market cap of $881M and EV of $855M.
Equity research analysts estimate Sanofi India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sanofi India has a P/E ratio of 22.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $881M | XXX | $881M | XXX | XXX | XXX |
| EV (current) | $855M | XXX | $855M | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | 15.5x | XXX | 15.8x | XXX | XXX | XXX |
| EV/EBIT | 16.4x | XXX | 16.8x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.7x | XXX | XXX | XXX |
| P/E | 22.8x | XXX | 23.4x | XXX | XXX | XXX |
| EV/FCF | 19.7x | XXX | 18.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sanofi India Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sanofi India Margins & Growth Rates
Sanofi India's revenue in the last 12 month grew by 5%.
Sanofi India's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Sanofi India's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sanofi India's rule of X is 45% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sanofi India Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sanofi India Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| Bright Minds Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Basilea Pharmaceutica | XXX | XXX | XXX | XXX | XXX | XXX |
| MannKind | XXX | XXX | XXX | XXX | XXX | XXX |
| LB Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Theravance | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sanofi India M&A Activity
Sanofi India acquired XXX companies to date.
Last acquisition by Sanofi India was on XXXXXXXX, XXXXX. Sanofi India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sanofi India
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSanofi India Investment Activity
Sanofi India invested in XXX companies to date.
Sanofi India made its latest investment on XXXXXXXX, XXXXX. Sanofi India invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sanofi India
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sanofi India
| When was Sanofi India founded? | Sanofi India was founded in 1956. |
| Where is Sanofi India headquartered? | Sanofi India is headquartered in India. |
| How many employees does Sanofi India have? | As of today, Sanofi India has over 991 employees. |
| Is Sanofi India publicly listed? | Yes, Sanofi India is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Sanofi India? | Sanofi India trades under SANOFI ticker. |
| When did Sanofi India go public? | Sanofi India went public in 2003. |
| Who are competitors of Sanofi India? | Sanofi India main competitors are Bright Minds Biosciences, Basilea Pharmaceutica, MannKind, LB Pharmaceuticals. |
| What is the current market cap of Sanofi India? | Sanofi India's current market cap is $881M. |
| What is the current revenue of Sanofi India? | Sanofi India's last 12 months revenue is $204M. |
| What is the current revenue growth of Sanofi India? | Sanofi India revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Sanofi India? | Current revenue multiple of Sanofi India is 4.2x. |
| Is Sanofi India profitable? | Yes, Sanofi India is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sanofi India? | Sanofi India's last 12 months EBITDA is $55M. |
| What is Sanofi India's EBITDA margin? | Sanofi India's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Sanofi India? | Current EBITDA multiple of Sanofi India is 15.5x. |
| What is the current FCF of Sanofi India? | Sanofi India's last 12 months FCF is $43M. |
| What is Sanofi India's FCF margin? | Sanofi India's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Sanofi India? | Current FCF multiple of Sanofi India is 19.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.